TAI'AN, China, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based biopharmaceutical companies in China, today announced that the Company's senior management team will ring the opening bell at the NASDAQ MarketSite in New York City at 9:30 a.m. ET on Tuesday, December 15, 2009.
China Biologic's common stock began trading on the NASDAQ Global Market on December 2, 2009, under the ticker symbol "CBPO."
"We are honored to ring the NASDAQ opening bell to celebrate our listing on one of the most prestigious equity markets in the world," said Mr. Chao Ming Zhao, China Biologic's Chief Executive Officer. "We would like to thank our shareholders, dedicated employees, board of directors, management team, and all other parties who have contributed to our success to date."
A live webcast of the NASDAQ Opening Bell (starting from 9:20 a.m. ET) will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and
Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in
Xi'an Huitian Blood Products Co., Ltd., is currently the largest
non-state-owned plasma-based biopharmaceutical company in China. The Company
is a fully integrated biologic products company with plasma collection,
production and manufacturing, research and development, and commercial
operations. The Company's plasma-based biopharmaceutical products are
irreplaceable during medical emergencies, and are used
|SOURCE China Biologic Products, Inc.|
Copyright©2009 PR Newswire.
All rights reserved